Conclusion
nausea and vomiting, vomiting
EFFECTS OF CHEMOTHERAPY, DELETION
This trial did not provide sufficient evidence to support that deletion of the NK-1 receptor antagonist was as good as keeping it, as a part of a 4-drug antiemetic regimen for highly emetogenic chemotherapy (ClinicalTrials.gov Identifier: NCT03578081).Nausea and vomiting are adverse effects of chemotherapy. This article reports a protocol developed to evaluate the value of an NK-1 receptor antagonist for preventing nausea and vomiting resulting from highly emetogenic chemotherapy with an olanzapine-based antiemetogenic regimen.